ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Sobi to refile Gamifant following CHMP rejection pharmatimes
July 28, 2020Sobi has announced its intent to file for a re-examination of Gamifant (emapalumab) in Europe following negative opinion by the European Medicines Agency's human medicines committee. -
Sobi snags FDA nod for rare disease drug Gamifant
fiercepharma
November 22, 2018Several months after scooping up global rights to emapalumab in a $452 million deal, Sobi has won?approval?for the drug to treat certain patients with?primary hemophagocytic lymphohistiocytosis.
Pharma Sources Insight January 2025
